Floatz logo

Ifx-Hu2.0

Merkel Cell Carcinoma

TuHURA Biosciences, Inc.vaccinePhase 2/3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Fludarabine
Sotio Biotech Inc.
Phase 2B
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B

View all 50 →

Same molecule, other indications

Ifx-Hu2.0 is also rated in:

skin carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
skin squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →